Abstract 1681P
Background
Adjuvant chemotherapy offers patients an improved chance of long-term survival, especially for those with R0/R1 resection. In APACT study, the median overall survival (mOS) of adjuvant chemotherapy for resectable pancreatic cancer (RPC) patients ranged from 36.2 to 40.5 months, but further improvement is still needed. As targeted therapy is still a blank in the treatment of RPC, we conducted this study, aiming to explore the clinical benefit of the addition of nimotuzumab to standard adjuvant chemotherapy.
Methods
RPC patients were treated with surgery, postoperative chemotherapy with or without nimotuzumab. Demographic and clinical data were collected from electronic medical records of Ruijin Hospital from May 2016 to July 2022. The primary efficacy endpoint was OS.
Results
We identified 795 patients who underwent surgical resection, of which 57 RPC patients received nimo. Propensity score matching (PSM) was performed to reduce the bias. After 1:1 PSM, we created 32 pairs RPC patients (stage I and II) who received adjuvant chemotherapy with nimo (study arm, Nimotuzumab 400mg, weekly, median exposure was 4 weeks) or without (control arm). Baseline characteristics were balanced after PSM. Median age was 63y, with 66% males. Barthel score 80-100. Median follow-up time was 35.2 (95%CI, 24.8-57.4) months and 37.3 (95%CI, 21.6-42.8) months in the control arm and study arm respectively. Survival analysis showed that study arm with a prolongation survival trend in OS (mOS: 24.5 months vs. 45.1 months) and disease-free survival (mDFS: 13.4 months vs. 15.4 months). Adverse events (AEs, Grade 1-2) were reported by 67% of patients (44 out of 64). The most frequently reported AEs were anemia (37.5%), leukopenia (7.8%), and diarrhea (4.7%), and there were no differences between the two groups. No Grade 3 or above adverse events were observed.
Conclusions
RPC patients were with a prolongation survival trend by the addition of nimotuzumab into current regimens in the postoperative program with good safety profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22
1580P - Early onset oesophageal adenocarcinoma: A separate biological entity?
Presenter: Dharmesh Valand
Session: Poster session 22
1581P - Total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with resectable locally advanced gastric and gastroesophageal junction cancer
Presenter: Maria Sedova
Session: Poster session 22
1582P - Gastroesophageal adenocarcinoma in young adults: Retrospective analysis of clinical and molecular features
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1583P - Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis
Presenter: Niels Guchelaar
Session: Poster session 22
1585P - The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
Presenter: Yoshiyasu Kono
Session: Poster session 22
1587P - Analysis of survival outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: A retrospective nationwide cohort study
Presenter: Tae-Hwan Kim
Session: Poster session 22
1588P - Analysis of risk factors of anastomotic leakage after minimally invasive esophagectomy with circular cervical anastomosis
Presenter: ming lu
Session: Poster session 22